FUNDAMENTALS |
MarketCap: |
11 956 mill
|
EPS: |
-5.80
|
P/E: |
-21.96
|
Earnings Date: |
May 01, 2024 |
SharesOutstanding: |
93.86 mill
|
Avg Daily Volume: |
0.822 mill
|
RATING
2024-04-25 |
S-
|
Strong Buy
|
RATINGS |
Rating CashFlow: |
Buy
|
|
Return On Equity: |
Buy
|
|
Return On Asset: |
Buy
|
|
DE: |
Strong Buy
|
|
P/E: |
Strong Buy
|
|
Price To Book: |
Strong Buy
|
|
QUARTER GROWTHS |
|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -21.96 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-3.74x
|
Company: PE -21.96 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 123.74 - 131.04
( +/- 2.87%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-03-08 | Wigzell Hans Lennart Rudolf | Buy | 15 000 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 3 155 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 11 745 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 100 | Common Stock |
2024-03-08 | Wigzell Hans Lennart Rudolf | Sell | 15 000 | Stock Option (right to buy) |
INSIDER POWER |
36.03
|
Last
100 transactions |
Buy:
408 419 | Sell:
153 150 |
Forecast:
16:00 - $127.39
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $127.39
Forecast 2: 16:00 - $127.39
Forecast 3: 16:00 - $127.39
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$127.39 (2.53% )
|
Volume |
1.487 mill
|
Avg. Vol. |
0.822 mill
|
% of Avg. Vol |
180.94 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For SRPT
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:35 | sell | $127.34 | N/A | Active |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.